Business Description
HUTCHMED (China) Ltd
ISIN : KYG4672N1198
Total Employee Number:
1,796Compare
Compare
Traded in other countries / regions
HCM.UK00013.Hong KongHCM.USAH7T1.Germany Index Membership
Hong Kong Stock Connect IPO Date
2021-06-30Description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 14.55 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | 0.18 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.69 | |||||
Beneish M-Score | -1.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year FCF Growth Rate | 36.4 | |||||
3-Year Book Growth Rate | 22 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -41.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.24 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.08 | |||||
9-Day RSI | 75.68 | |||||
14-Day RSI | 71.82 | |||||
3-1 Month Momentum % | 10.43 | |||||
6-1 Month Momentum % | -12.17 | |||||
12-1 Month Momentum % | -22.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.64 | |||||
Quick Ratio | 5.5 | |||||
Cash Ratio | 5 | |||||
Days Inventory | 46.62 | |||||
Days Sales Outstanding | 86.19 | |||||
Days Payable | 46.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.6 | |||||
Shareholder Yield % | -0.13 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 41.56 | |||||
Operating Margin % | -5.69 | |||||
Net Margin % | 3.26 | |||||
EBITDA Margin % | 94.55 | |||||
FCF Margin % | 1.81 | |||||
OCF Margin % | 3.73 | |||||
ROE % | 1.45 | |||||
ROA % | 1.03 | |||||
ROIC % | -7.68 | |||||
3-Year ROIIC % | -680.38 | |||||
ROC (Joel Greenblatt) % | 532.34 | |||||
ROCE % | 35.15 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 138 | |||||
Forward PE Ratio | 28.01 | |||||
PE Ratio without NRI | 147.86 | |||||
Price-to-Owner-Earnings | 6.25 | |||||
PS Ratio | 4.39 | |||||
PB Ratio | 1.9 | |||||
Price-to-Tangible-Book | 1.9 | |||||
Price-to-Free-Cash-Flow | 230.97 | |||||
Price-to-Operating-Cash-Flow | 115.49 | |||||
EV-to-EBIT | 2.26 | |||||
EV-to-Forward-EBIT | -34.44 | |||||
EV-to-EBITDA | 2.2 | |||||
EV-to-Forward-EBITDA | -130.99 | |||||
EV-to-Revenue | 2.07 | |||||
EV-to-Forward-Revenue | 1.9 | |||||
EV-to-FCF | 115.75 | |||||
Price-to-GF-Value | 1.05 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
Price-to-Graham-Number | 3.52 | |||||
| Price-to-Net-Current-Asset-Value | 2.24 | |||||
| Price-to-Net-Cash | 2.67 | |||||
Earnings Yield (Greenblatt) % | 44.25 | |||||
FCF Yield % | 0.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HUTCHMED (China) Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 4,288.443 | ||
| EPS (TTM) (HK$) | 0.157 | ||
| Beta | 1.0996 | ||
| 3-Year Sharpe Ratio | -0.06 | ||
| 3-Year Sortino Ratio | -0.09 | ||
| Volatility % | 28.59 | ||
| 14-Day RSI | 71.82 | ||
| 14-Day ATR (HK$) | 0.93776 | ||
| 20-Day SMA (HK$) | 19.9745 | ||
| 12-1 Month Momentum % | -22.14 | ||
| 52-Week Range (HK$) | 15.57 - 28.8 | ||
| Shares Outstanding (Mil) | 869.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HUTCHMED (China) Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HUTCHMED (China) Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-05 13:00 | In 179 days | ||
| Annual report for 2026 | 2027-03-05 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-05 | In 178 days | ||
| HUTCHMED Business Update Webcast | 2026-09-03 07:30 | 19.14 (+1.00%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 08:00 | 17.96 (+2.34%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 17.96 (+2.34%) | ||
| General meeting for 2026 | 2026-05-12 16:00 | 20.32 (-3.24%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 13:00 | 20.84 (-1.14%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 11:00 | 20.84 (-1.14%) | ||
| Annual report for 2025 | 2026-03-05 | 20.84 (-1.14%) |
Show
Entries
HUTCHMED (China) Ltd Frequently Asked Questions
What is HUTCHMED (China) Ltd(HKSE:00013)'s stock price today?
The current price of HKSE:00013 is HK$22.10. The 52 week high of HKSE:00013 is HK$28.80 and 52 week low is HK$15.57.
When is next earnings date of HUTCHMED (China) Ltd(HKSE:00013)?
The next earnings date of HUTCHMED (China) Ltd(HKSE:00013) is 2027-03-05 Est..
Does HUTCHMED (China) Ltd(HKSE:00013) pay dividends? If so, how much?
HUTCHMED (China) Ltd(HKSE:00013) does not pay dividend.
Press Release
Articles on HUTCHMED (China) Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers